Mölnlycke to co-promote Endoform in the US as Aroa Biosurgery holds FY27 guidance
Aroa Biosurgery (ASX: ARX) has entered into an exclusive agreement with Mölnlycke Healthcare US for Endoform co-promotion in the United States, effective 16 October 2026.
The arrangement is intended to expand access to Endoform in the US post-acute setting and support the product’s continued growth. FY27 financial guidance remains unchanged.
For investors, a partner described in the announcement as having an “established market leading position and commercial reach” extends Endoform’s reach, while AROA’s direct sales team is able to focus on strategic priorities.
When big ASX news breaks, our subscribers know first
What the agreement covers
The announcement sets out a narrow scope. Financial terms, fees and duration were not disclosed.
Scope and ownership
- The agreement relates solely to Endoform for post-acute settings in the United States market.
- AROA retains ownership of Endoform and AROA ECM technology.
- AROA will continue to manufacture, distribute and supply Endoform.
- AROA’s other product portfolios and commercial arrangements, including Endoform distribution outside the United States, remain unchanged.
The source describes the arrangement as a co-promotion only, and does not characterise it as a sale, licence or transfer of rights.
Unchanged FY27 guidance
AROA confirmed its FY27 full year financial guidance remains unchanged.
| Metric | FY27 guidance | Status |
|---|---|---|
| Total revenue | NZ$115-125 million | Unchanged |
| Normalised EBITDA | $8-11 million | Unchanged |
Note: Normalised EBITDA is non-conforming financial information, as defined by the NZ Financial Markets Authority.
The reaffirmed ranges follow FY26 results that beat guidance on every key metric, with a debt-free balance sheet and a planned NZ$9m growth investment sitting behind the FY27 targets.
Co-promotion explained for investors
Co-promotion generally means a partner’s sales force markets a product alongside its owner. Here, AROA keeps ownership of Endoform and continues to manufacture, distribute and supply it, so the arrangement is not a sale or a distribution handover.
Endoform products are extracellular matrix products, composed of AROA ECM, for the management of acute and chronic wounds in the outpatient or post-acute settings.
Mölnlycke Health Care is described as a world-leading MedTech company whose products are used in over 100 countries. Founded in 1849, it is owned by Patricia Industries, part of Investor AB, and is headquartered in Sweden.
The structure allows AROA to draw on a partner’s commercial reach without giving up product ownership or manufacturing.
Refocusing on Myriad and Symphony
The agreement is also intended to allow AROA to focus its resources on key strategic priorities. These include growing Myriad’s adoption in surgical settings and pursuing the current opportunity for Symphony in the outpatient setting.
The announcement does not quantify either opportunity. Management attention and direct sales capacity are directed at these identified priorities.
Symphony trial data showed 55% complete wound closure at 12 weeks versus 35% for standard care, evidence that underpins management’s push into the outpatient setting.
Brian Ward, Founder and CEO, AROA
“Mölnlycke’s deep expertise in wound care and broad commercial footprint provide a strong platform to bring Endoform to more clinicians and patients.”
Mr Ward also said the arrangement allows AROA to concentrate on its strategic priorities.
Brian Ward, Founder and CEO, AROA
“…sustaining Myriad’s growth and pursuing the significant opportunity for Symphony, while continuing to manufacture and supply Endoform.”
Craig Kennedy, VP Americas, Mölnlycke
“…By adding Endoform to our advanced wound dressing portfolio, we’re expanding the solutions available to clinicians and addressing the diverse need of the patients they serve.”
What to watch next
The agreement is effective 16 October 2026, and FY27 guidance has been reaffirmed. The announcement gives no timelines or financial terms.
AROA states that over 7 million AROA devices have been used globally to date. Distribution into its key market of the United States is via its direct sales force and its partner TELABio, Inc.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX alerts within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get healthcare and other non-resource news in your inbox the moment it breaks.